BLUE BELL, Pa., June 22 /PRNewswire/ — TheraQuest
Biosciences, Inc., a clinical stage pain management company today
unveiled its analgesic product pipeline. TheraQuest also announced
the launch of its new corporate website at http://www.theraquestinc.com.
Najib Babul, PharmD, President and Chief Executive Officer,
said, “After a careful strategic review of our pipeline, we have
realigned our development efforts to focus on chronic pain products
with the largest market potential and greatest probability for
timely FDA approval.” Babul further noted, “Going forward, we
will focus our development resources on drugs to treat chronic
musculoskeletal conditions such as osteoarthritis and low back
pain, and on neuropathic pain.”
Overview of Pain Pipeline
TQ-1020 (Levorphanol Extended Release) is a
proprietary once-a-day extended release levorphanol in an abuse
deterrent drug delivery system. It has activity at both opioid and
non-opioid receptors and monoamine reuptake inhibition comparable
to Nucynta® and Ultram®.
TQ-1021 (Topical Mepivacaine) is a proprietary topical
dosage form of the local anesthetic, mepivacaine for the treatment
of neuropathic pain. It has been granted Orphan Drug Designations
for the treatment of postherpetic neuralgia and painful HIV
neuropathy.
TQ-1028 (Oral, Buprenorphine Extended Release) is
a proprietary once-a-day extended release oral dosage form of the
C-III opioid buprenorphine. According to the DEA and FDA,
buprenorphine has a l
‘/>”/>
SOURCE
